<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881112466182</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881112466182</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Humpston</surname><given-names>Clara S</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Wood</surname><given-names>Christian M</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Robinson</surname><given-names>Emma SJ</given-names></name>
</contrib>
<aff id="aff1-0269881112466182">School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269881112466182">Emma SJ Robinson, School of Physiology and Pharmacology, University of Bristol, Medical Sciences Building, University Walk, Bristol, BS8 1TD, UK. Email: <email>pmesjr@bris.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>27</volume>
<issue>2</issue>
<fpage>213</fpage>
<lpage>221</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Previous studies have shown that drugs which block the reuptake of catecholamine neurotransmitters improve impulse control in diseases such as attention deficit hyperactivity disorder (ADHD). Serotonin-specific reuptake inhibitors (SSRI) lack efficacy in ADHD and have been linked to increased suicide risk. The present study investigated drugs with affinity for one or more of the monoamine reuptake transporters using the 5-choice serial reaction time task, a model of attention and impulsivity in rodents. We also tested the effects of the alpha<sub>2</sub>-adreoceptor antagonist, idazoxan and novel antidepressant, agomelatine, which both increase cortical noradrenaline concentrations through non-reuptake mechanisms. Improvements in impulse control were observed with venlafaxine, a serotonin and noradrenaline re-uptake inhibitor (SNRI) but not bupropion (dopamine and noradrenaline re-uptake inhibitor). Sibutramine (SNRI) reduced premature responses by ~50% at the highest dose tested but this was not significant. All three of the SSRIs tested reduced premature responding in a dose-dependent manner, although also slowed response and collection latencies. Neither idazoxan nor agomelatine significantly reduced premature responding, suggesting a lack of efficacy at the doses tested. None of the drugs tested improved attention in this task but sibutramine (SNRI), fluoxetine (SSRI) and paroxetine (SSRI) all increased omissions at the highest dose tested. These data suggest that the SNRIs and SSRIs reduce premature responding but tend to be less specific than noradrenaline specific reuptake inhibitors in this model. SSRIs did not induce any specific impairment in impulse control in this model.</p>
</abstract>
<kwd-group>
<kwd>Noradrenaline</kwd>
<kwd>dopamine</kwd>
<kwd>serotonin</kwd>
<kwd>attention</kwd>
<kwd>impulsivity</kwd>
<kwd>5-choice serial reaction time task</kwd>
<kwd>ADHD</kwd>
<kwd>rat</kwd>
<kwd>monoamine reuptake</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881112466182" sec-type="intro">
<title>Introduction</title>
<p>Impulsivity, by definition, includes ‘actions that are poorly conceived, prematurely expressed, unduly risky, or inappropriate to the situation and that often result in undesirable outcomes’ (<xref ref-type="bibr" rid="bibr26-0269881112466182">Evenden, 1999a</xref>). While impulsive behaviour itself is not a diagnostic entity, failures in impulse control are often featured in psychiatric disorders such as attention deficit hyperactivity disorder (ADHD), personality disorders and substance misuse (<xref ref-type="bibr" rid="bibr18-0269881112466182">Chamberlain and Sahakian, 2007</xref>; <xref ref-type="bibr" rid="bibr79-0269881112466182">Zapolski et al., 2010</xref>). Schizophrenia and bipolar mania, two of the disorders at the most severe end of the psychopathology ‘spectrum’, are also associated with impulsivity (<xref ref-type="bibr" rid="bibr50-0269881112466182">Nolan et al., 2011</xref>). In addition, it has been proposed that suicidal and self-injurious behaviours may have an impulsive nature as well (<xref ref-type="bibr" rid="bibr38-0269881112466182">Javdani et al., 2011</xref>).</p>
<p>The first-line treatment for most psychiatric disorders remains the use of psychotropic medications; however, impulsivity as a personality trait has been somewhat resistant to drug treatment (<xref ref-type="bibr" rid="bibr27-0269881112466182">Evenden, 1999b</xref>). Indeed, there is no specific drug indicated for impulsivity, even though there is plenty of research evidence supporting its biological basis. Current treatments for ADHD are drugs such as methylphenidate and atomoxetine, which primarily target the catecholamine transmitters, noradrenaline and dopamine (<xref ref-type="bibr" rid="bibr2-0269881112466182">Arnsten, 2006</xref>; <xref ref-type="bibr" rid="bibr14-0269881112466182">Braquehais et al., 2010</xref>; <xref ref-type="bibr" rid="bibr72-0269881112466182">Wilens, 2006</xref>). The serotonergic systems are thought to be dysfunctional in some impulsive behaviours (<xref ref-type="bibr" rid="bibr19-0269881112466182">Chamberlain et al., 2006</xref>; <xref ref-type="bibr" rid="bibr71-0269881112466182">Walderhaug et al., 2002</xref>; <xref ref-type="bibr" rid="bibr70-0269881112466182">2008</xref>); however, serotonin-specific reuptake inhibitors (SSRI) lack efficacy in ADHD (<xref ref-type="bibr" rid="bibr30-0269881112466182">Fone and Nutt, 2005</xref>). Serotonin (5-HT) has also been discussed in relation to a role in suicide, where effects on impulse control may be a relevant factor (<xref ref-type="bibr" rid="bibr40-0269881112466182">Kamali et al., 2001</xref>; <xref ref-type="bibr" rid="bibr55-0269881112466182">Perroud et al., 2011</xref>; although also see <xref ref-type="bibr" rid="bibr33-0269881112466182">Gvion and Apter, 2011</xref>). Although the 5-HT system is thought to be closely associated with suicidality, with the 5-HT transporter (5-HTT) playing a major role (<xref ref-type="bibr" rid="bibr44-0269881112466182">Mann et al., 2001</xref>; <xref ref-type="bibr" rid="bibr56-0269881112466182">Purselle and Nemeroff, 2003</xref>), no direct relationship has been established. A relationship between SSRI treatment for depression and adverse effects such as increased suicide risk and self-harming behaviours has also been the subject of much debate (<xref ref-type="bibr" rid="bibr58-0269881112466182">Reid and Barbui, 2010</xref>).</p>
<p>The roles of the monoamines in impulse control have been investigated using many different rodent paradigms (<xref ref-type="bibr" rid="bibr22-0269881112466182">Dalley et al., 2008</xref>; <xref ref-type="bibr" rid="bibr29-0269881112466182">Floresco and Jentsch, 2011</xref>). Impulsivity consists of several different behavioural dimensions which have been anatomically and pharmacologically dissociated (<xref ref-type="bibr" rid="bibr21-0269881112466182">Dalley et al., 2011</xref>; <xref ref-type="bibr" rid="bibr25-0269881112466182">Eagle and Baunez, 2010</xref>; <xref ref-type="bibr" rid="bibr26-0269881112466182">Evenden, 1999a</xref>, <xref ref-type="bibr" rid="bibr27-0269881112466182">1999b</xref>; <xref ref-type="bibr" rid="bibr53-0269881112466182">Pattij and Vanderschuren, 2008</xref>; <xref ref-type="bibr" rid="bibr73-0269881112466182">Winstanley, 2011</xref>). The 5-choice serial reaction time task (5-CSRTT) assesses animals’ performance and/or impairments in sustained and spatially divided attention, with good construct validity (<xref ref-type="bibr" rid="bibr5-0269881112466182">Bari et al., 2008</xref>). It requires the rat to maintain attention in order to monitor the apertures and refrain from responding prematurely, i.e. before the presentation of stimulus. Failure to withhold from responding before the stimulus results in an anticipatory response, which is thought to represent a failure in inhibitory control. Previous studies have shown that noradrenaline re-uptake inhibitors (NRI) such as atomoxetine improve impulse control (<xref ref-type="bibr" rid="bibr13-0269881112466182">Blondeau and Dellu-Hagedorn, 2006</xref>; <xref ref-type="bibr" rid="bibr29-0269881112466182">Floresco and Jentsch, 2011</xref>; <xref ref-type="bibr" rid="bibr49-0269881112466182">Navarra et al., 2008</xref>; <xref ref-type="bibr" rid="bibr61-0269881112466182">Robinson et al., 2008a</xref>; <xref ref-type="bibr" rid="bibr69-0269881112466182">Tsutsui-Kimura et al., 2009</xref>) and attention in the 5-CSRTT (<xref ref-type="bibr" rid="bibr60-0269881112466182">Robinson, 2012</xref>). The effects of serotonergic manipulations in this task are less clear and may reflect differential roles of the many 5-HT receptor subtypes within different brain regions (<xref ref-type="bibr" rid="bibr4-0269881112466182">Baarendse and Vanderschuren, 2012</xref>; <xref ref-type="bibr" rid="bibr22-0269881112466182">Dalley et al., 2008</xref>; <xref ref-type="bibr" rid="bibr74-0269881112466182">Winstanley et al., 2006</xref>). In a study using rats trained in the stop-signal reaction time (SSRT) task, <xref ref-type="bibr" rid="bibr6-0269881112466182">Bari et al. (2009)</xref> demonstrated a dissociable effect on the performance of the SSRT task by three different monoamine reuptake inhibitors: citalopram (SSRI), atomoxetine (NRI) and GBR-12909 (dopamine re-uptake inhibitor). Whilst atomoxetine improved impulse control, citalopram lacked efficacy and GBR-12909 induced general effects on motor activity. In a study by <xref ref-type="bibr" rid="bibr4-0269881112466182">Baarendse and Vanderschuren (2012)</xref>, the effects of different monoamine reuptake inhibitors were investigated using the 5-CSRTT and delayed reward task. In this study, citalopram and atomoxetine were found to improve impulsive action but not impulsive choice, whilst blockade of dopamine reuptake increased impulsive action but improved impulsive choice.</p>
<p>The present study has investigated a number of monoamine reuptake inhibitors which have been approved for the treatment of different psychiatric disorders including depression, obesity and nicotine dependence. Using the 5-CSRTT, this study compared acute treatments with a number of different re-uptake inhibitors which increase synaptic levels of one of more of the monoamine transmitters in the frontal cortex. Based on their relative affinity for the different monoamine re-uptake sites, fluoxetine, citalopram and paroxetine are classed as SSRIs; venlafaxine and sibutramine are dual serotonin–noradrenaline reuptake inhibitors (SNRI) (<xref ref-type="bibr" rid="bibr12-0269881112466182">Beyer et al., 2002</xref>; <xref ref-type="bibr" rid="bibr36-0269881112466182">Heal et al., 1998</xref>; <xref ref-type="bibr" rid="bibr66-0269881112466182">Stahl et al., 2005</xref>), and bupropion inhibits the reuptake of noradrenaline and dopamine (<xref ref-type="bibr" rid="bibr17-0269881112466182">Carroll et al., 2009</xref>). Regulation of impulse control and attention is thought to involve optimal function in the prefrontal cortex (PFC) (<xref ref-type="bibr" rid="bibr22-0269881112466182">Dalley et al., 2008</xref>); therefore, the neurochemical effects of these drugs in this region are particularly relevant to this study. The SSRIs have been shown to produce increases in cortical serotonin; however, these effects may be transient due to autoreceptor activation (<xref ref-type="bibr" rid="bibr8-0269881112466182">Bel and Artigas, 1999</xref>; <xref ref-type="bibr" rid="bibr64-0269881112466182">Rutter et al., 1995</xref>). There is also evidence that certain SSRIs increase cortical noradrenaline (for example see <xref ref-type="bibr" rid="bibr12-0269881112466182">Beyer et al., 2002</xref>; <xref ref-type="bibr" rid="bibr39-0269881112466182">Jordan et al., 1994</xref>; <xref ref-type="bibr" rid="bibr68-0269881112466182">Thomas et al., 1998</xref>; <xref ref-type="bibr" rid="bibr80-0269881112466182">Zhang et al., 2000</xref>). Despite in vitro studies suggesting a higher affinity for the serotonin versus noradrenaline transporter (<xref ref-type="bibr" rid="bibr66-0269881112466182">Stahl et al., 2005</xref>), microdialysis studies in the PFC suggest that venlafaxine has greater effects on cortical noradrenaline (<xref ref-type="bibr" rid="bibr12-0269881112466182">Beyer et al., 2002</xref>). Sibutramine has been shown to increase synaptic concentrations of both serotonin and noradrenaline with little effect on dopamine (<xref ref-type="bibr" rid="bibr32-0269881112466182">Gundlah et al. 1997</xref>; <xref ref-type="bibr" rid="bibr63-0269881112466182">Rowley et al., 2000</xref>; <xref ref-type="bibr" rid="bibr76-0269881112466182">Wortley et al. 1999</xref>). Although not all of the studies investigated effects on dopamine, drugs which block the noradrenaline transporter in the PFC are likely to also affect cortical dopamine (<xref ref-type="bibr" rid="bibr78-0269881112466182">Yamamoto and Novotney, 1998</xref>). Studies using the selective NRI atomoxetine showed a significant increase in cortical but not sub-cortical dopamine, an effect hypothesised to contribute to its efficacy in ADHD and impulse control (<xref ref-type="bibr" rid="bibr67-0269881112466182">Swanson et al., 2006</xref>). Given the hypothesis that increased cortical noradrenaline may be beneficial in impulse control, we also investigated two drugs which have been shown to increase noradrenaline through non-reuptake mechanisms. Agomelatine, a melatonergic agonist and 5-HT<sub>2C</sub> antagonist antidepressant has been shown to increase noradrenaline levels in cortex (<xref ref-type="bibr" rid="bibr47-0269881112466182">Millan et al., 2003</xref>), and idazoxan is an alpha2-adrenoceptor antagonist and has also been shown to increase both cortical noradrenaline and dopamine (<xref ref-type="bibr" rid="bibr10-0269881112466182">Bengtsson et al., 2000</xref>; <xref ref-type="bibr" rid="bibr24-0269881112466182">Devoto et al., 2001</xref>).</p>
</sec>
<sec id="section2-0269881112466182" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0269881112466182">
<title>Subjects</title>
<p>The subjects were 18 male Lister-hooded rats weighing approximately 250 g at the start of training and 350–450 g at the start of dosing (Harlan, UK), housed in groups of four with standard environmental enrichment (bedding and cardboard tubes) under temperature-controlled conditions and 12-h:12-h reverse light-dark cycle (lights off at 0700 hours). They were maintained at approximately 90% of their free feeding weight by restricting access to laboratory chow (Purina, UK) to ~18 g/day per rat. Water was provided ad libitum. All procedures were conducted in accordance with the requirements of the UK Animals (Scientific Procedures) Act 1986 and were approved by the local ethical review panel. All behavioural testing was carried out between 0800 and 1700 hours, during the animals’ active phase.</p>
</sec>
<sec id="section4-0269881112466182">
<title>Five-choice serial reaction time task</title>
<p>All testing was carried out using standard rat 5-hole operant boxes manufactured by Med Associates, USA (Sandown Scientific, UK). Each chamber was housed in a sound-attenuating chamber controlled by K-Limbic Software (Conclusive Solutions Ltd, UK) programmed to run the 5-CSRTT protocols and record the data. Subjects were trained to detect the location of a brief visual stimulus (0.5 sec) presented pseudorandomly in one of five apertures over 100 trials, as described previously (<xref ref-type="bibr" rid="bibr20-0269881112466182">Dalley et al. 2004</xref>). This task can be used to study visuo-spatial attention and impulse control in rats through analysis of different performance variables (<xref ref-type="bibr" rid="bibr59-0269881112466182">Robbins, 2002</xref>). Animals were run with the house light illuminated, but incorrect, omitted and premature responses errors were punished with a 5 s timeout when all lights were switched off. A number of performance measures were recorded: choice accuracy (the proportion of correct responses to the total number of correct and incorrect responses) which reflects the ability to detect and respond in the correct aperture; omissions (a failure to respond within the limited hold (LH)), which are thought to more closely relate to sensory, motor or motivational factors than attentional accuracy (<xref ref-type="bibr" rid="bibr59-0269881112466182">Robbins, 2002</xref>); premature responding (the proportion of anticipatory responses made relative to the total trials), which provides a measure of response inhibition and the ability to withhold from making a response until the presentation of the cue; correct response latency (the time from the stimulus onset to a correct response) and magazine latency (the time from a correct response to the collection of food in the magazine), which both provide indices of motivational, sedative or motor effects. Perseverative responding (repeated responses at the response apertures) was not punished and although recorded, the data showed a high degree of variability and were not analysed further. Subjects were trained using graduated stages and were considered to have acquired the task when their accuracy at 0.5 s stimulus, 5 s LH and 5 sec inter-trial interval (ITI) was greater than 80% and omissions were fewer than 20%. Once animals reached criterion, baseline performance was stabilised for at least 10 further sessions.</p>
<p>Once animals had reached a stable level of performance, fully randomised within-subject dose–response experiments were carried out. All animals were used for each drug tested and all doses using counter-balanced study design. At the end of each drug testing schedule, animals were not tested for a week and underwent five further baseline sessions before starting the next compound, giving a minimum of 2 weeks’ washout between drug treatments. Animals received baseline sessions on Monday and Thursday, drug dosing and testing was carried out on Tuesday and Friday and there was no dosing or testing on Wednesday, Saturday or Sunday.</p>
</sec>
<sec id="section5-0269881112466182">
<title>Drugs</title>
<p>Bupropion hydrochloride, venlafaxine hydrochloride, sibutramine hydrochloride, idazoxan, fluoxetine hydrochloride, citalopram hydrobromide and paroxetine hydrochloride were purchased from Tocris Bioscience (Bristol, UK) and agomelatine was purchased from Sigma, UK. All drugs were dissolved in 0.9% saline except for agomelatine, which was dissolved in a cremophor/DMSO/saline solution in the ratio 1:2:8. All drugs were administered by intraperitoneal (i.p.) injection in a final volume of 1 mL/kg, 40 min prior to the start of behavioural testing. Drugs were prepared fresh each day. In our previous studies (<xref ref-type="bibr" rid="bibr60-0269881112466182">Robinson, 2012</xref>; <xref ref-type="bibr" rid="bibr61-0269881112466182">Robinson et al., 2008a</xref>) we have found specific effects on impulse control and attention with atomoxetine and reboxetine at doses much lower than those used in non-operant behaviour tests. We also observed that higher doses of these drugs started to induce non-specific effects such as increased omissions and latencies, suggesting effects on motivation to perform the task. For the monoamine re-uptake inhibitors, we therefore chose doses approximately 10-fold lower than those published in other behavioural tasks. Once we had completed the initial dose–response experiment, the results were analysed to determine if any effects were observed and whether the highest dose was starting to show non-specific effects on motivation. The doses for idazoxan were based on our previous studies using the forced-choice version of the 5CSRTT (data unpublished). Agomelatine has been shown to induce neurochemical effects at relatively high doses, but limited availability of the compound restricted our maximum dose to 1 mg/kg.</p>
</sec>
<sec id="section6-0269881112466182">
<title>Statistical analysis</title>
<p>All statistical analyses were carried out using SPSS (version 19.0, IBM, USA) for Windows. The six behavioural parameters described above in the drug experiments were analysed using a repeated measures analysis of variance (ANOVA) with treatment as factor. The significance level of all tests conducted was α=0.05, and post hoc comparisons were performed following repeated measures ANOVA (Dunnett’s Multiple Comparison Test against vehicle for dosing data and Tukey’s Multiple Comparison Test against all columns for baseline data).</p>
</sec>
</sec>
<sec id="section7-0269881112466182" sec-type="results">
<title>Results</title>
<sec id="section8-0269881112466182">
<title>Pre-testing baseline</title>
<p>Following 10 days of baseline testing, all animals reached a stable level of performance in the task with no significant differences found for any of the quantified variables found across the last three days of testing (data not shown).</p>
</sec>
<sec id="section9-0269881112466182">
<title>Experiment 1: Effects of the mixed action reuptake inhibitors, venlafaxine, sibutramine and bupropion on performance in the 5-CSRTT</title>
<p>Venlafaxine (0.1–3.0 mg/kg, i.p.) significantly reduced premature responding [<italic>F</italic> (3.0, 51.3)=3.269, <italic>p</italic>=0.028]; post hoc pair-wise comparison revealed that this decrease occurred at 0.3 mg/kg and 3.0 mg/kg. Sibutramine (0.3–3.0 mg/kg, i.p.) did not significantly reduce premature responding [<italic>F</italic> (2.7, 46.6)=1.513, <italic>p</italic>=0.23]; however, the highest dose did reduce premature responding by ~50% (~4% to ~2%). Bupropion (0.1–3.0 mg/kg, i.p.) had no observable effect on premature responses [<italic>F</italic> (4.0, 68.0)=0.697, <italic>p</italic>=0.60].</p>
<p>No significant effects on accuracy [<italic>F</italic> (3.9, 66.4)=0.726, <italic>p</italic>=0.57] or omissions [<italic>F</italic> (3.4, 57.5)=0.881, <italic>p</italic>=0.47] were observed following venlafaxine treatment, but the highest doses significantly increased correct latency [<italic>F</italic> (3.2, 54.9)=4.170, <italic>p</italic>=0.008] and tended to increase collection latency [<italic>F</italic> (2.7, 46.6)=2.383, <italic>p</italic>=0.086]. Bupropion did not affect accuracy [<italic>F</italic> (4.0, 68.0)=0.574, <italic>p</italic>=0.68], omissions [<italic>F</italic> (2.8, 47.5)=0.741, <italic>p</italic>=0.52] or correct latency and collection latency (<italic>F</italic>&lt;1.0, <italic>p</italic>&gt;0.32). Sibutramine had no effect on accuracy [<italic>F</italic> (3.0, 51.0)=1.063, <italic>p</italic>=0.37]; however, it significantly increased omitted responses [<italic>F</italic> (1.5, 24.8)=4.665, <italic>p</italic>=0.028]. Post hoc pair-wise comparisons demonstrated that this effect only occurred at the highest dose tested (3.0 mg/kg). It also significantly increased correct latency [<italic>F</italic> (2.1, 35.2)=3.759, <italic>p</italic>=0.032], although no significant difference were observed following post hoc pair-wise comparisons. Collection latency was not significantly affected [<italic>F</italic> (1.7, 29.2)=0.936, <italic>p</italic>=0.39]. Results are presented in <xref ref-type="fig" rid="fig1-0269881112466182">Figure 1</xref> and <xref ref-type="table" rid="table1-0269881112466182">Table 1</xref>.</p>
<fig id="fig1-0269881112466182" position="float">
<label>Figure 1.</label>
<caption>
<p>Effects of the mixed monoamine reuptake inhibitors, venlafaxine (0.0–3.0 mg/kg, i.p), bupropion (0.0–3.0 mg/kg, i.p) and sibutramine (0.0–3.0 mg/kg, i.p.) on the percent correct, omission and premature responses (<italic>n</italic>=18). Data shown as mean ± s.e. mean. *denotes <italic>p</italic>&lt;0.05 compared with vehicle treatment.</p>
</caption>
<graphic xlink:href="10.1177_0269881112466182-fig1.tif"/></fig>
<table-wrap id="table1-0269881112466182" position="float">
<label>Table 1.</label>
<caption>
<p>Effects of treatment on the latencies to respond to the cue (response latency) or collect the reward (collection latency).</p>
</caption>
<graphic alternate-form-of="table1-0269881112466182" xlink:href="10.1177_0269881112466182-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Treatment</th>
<th align="left">Dose (mg/kg)</th>
<th align="left">Correct Latency (csec)</th>
<th align="left">Collection Latency (csec)</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Venlafaxine</bold></td>
<td>0</td>
<td>50.48 ± 1.717</td>
<td>146.1 ± 8.271</td>
</tr>
<tr>
<td/>
<td>0.1</td>
<td>53.96 ± 2.434</td>
<td>141.9 ± 6.240</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td><bold>56.25 ± 2.006<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td>140.2 ± 6.147</td>
</tr>
<tr>
<td/>
<td>1</td>
<td><bold>56.23 ± 2.428<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td>139.0 ± 5.529</td>
</tr>
<tr>
<td/>
<td>3</td>
<td><bold>58.01 ± 2.045<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td>153.3 ± 7.535</td>
</tr>
<tr>
<td><bold>Bupropion</bold></td>
<td>0</td>
<td>55.02 ± 2.067</td>
<td>139.8 ± 6.738</td>
</tr>
<tr>
<td/>
<td>0.1</td>
<td>52.52 ± 1.727</td>
<td>137.4 ± 4.860</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>51.76 ± 1.829</td>
<td>134.7 ± 4.465</td>
</tr>
<tr>
<td/>
<td>1</td>
<td>53.50 ± 2.273</td>
<td>136.3 ± 5.138</td>
</tr>
<tr>
<td/>
<td>3</td>
<td>53.74 ± 2.420</td>
<td>139.3 ± 7.156</td>
</tr>
<tr>
<td><bold>Sibutramine</bold></td>
<td>0</td>
<td>59.08 ± 2.062</td>
<td>138.3 ± 4.900</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>57.19 ± 2.325</td>
<td>136.5 ± 5.756</td>
</tr>
<tr>
<td/>
<td>1</td>
<td>57.26 ± 2.377</td>
<td>163.5 ± 24.45</td>
</tr>
<tr>
<td/>
<td>3</td>
<td>65.37 ± 3.231</td>
<td>163.0 ± 17.01</td>
</tr>
<tr>
<td><bold>Fluoxetine</bold></td>
<td>0</td>
<td>51.72 ± 1.479</td>
<td>145.3 ± 3.731</td>
</tr>
<tr>
<td/>
<td>0.1</td>
<td>53.63 ± 1.020</td>
<td>151.7 ± 5.269</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>52.13 ± 1.294</td>
<td>140.6 ± 4.281</td>
</tr>
<tr>
<td/>
<td>1</td>
<td>52.60 ± 1.820</td>
<td>146.6 ± 4.061</td>
</tr>
<tr>
<td/>
<td>3</td>
<td><bold>59.83 ± 1.866<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td><bold>164.8 ± 6.542<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
</tr>
<tr>
<td><bold>Citalopram</bold></td>
<td>0</td>
<td>51.55 ± 1.644</td>
<td>132.5 ± 5.960</td>
</tr>
<tr>
<td/>
<td>0.1</td>
<td>51.89 ± 1.652</td>
<td>140.8 ± 6.841</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>54.45 ± 1.835</td>
<td>139.5 ± 7.327</td>
</tr>
<tr>
<td/>
<td>1</td>
<td><bold>56.83 ± 2.132<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td>144.2 ± 7.077</td>
</tr>
<tr>
<td/>
<td>3</td>
<td><bold>57.86 ± 1.897<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td>152.1 ± 8.779<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></td>
</tr>
<tr>
<td><bold>Paroxetine</bold></td>
<td>0</td>
<td>51.50 ± 2.043</td>
<td>133.3 ± 5.572</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>54.75 ± 2.102</td>
<td>134.4 ± 4.791</td>
</tr>
<tr>
<td/>
<td>1</td>
<td><bold>58.42 ± 3.127<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td>141.8 ± 7.431</td>
</tr>
<tr>
<td/>
<td>3</td>
<td><bold>67.30 ± 2.701<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td><bold>156.0 ± 8.652<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
</tr>
<tr>
<td><bold>Idazoxan</bold></td>
<td>0</td>
<td>49.08 ± 1.615</td>
<td>125.9 ± 5.063</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>51.04 ± 1.941</td>
<td>129.4 ± 5.427</td>
</tr>
<tr>
<td/>
<td>1</td>
<td><bold>53.39 ± 1.626<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td>127.3 ± 4.681</td>
</tr>
<tr>
<td/>
<td>3</td>
<td><bold>53.10 ± 1.952<xref ref-type="table-fn" rid="table-fn1-0269881112466182">*</xref></bold></td>
<td>129.6 ± 3.888</td>
</tr>
<tr>
<td><bold>Agomelatine</bold></td>
<td>0</td>
<td>52.12 ± 2.678</td>
<td>132.2 ± 6.206</td>
</tr>
<tr>
<td/>
<td>0.1</td>
<td>51.97 ± 1.996</td>
<td>132.4 ± 6.180</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>51.11 ± 1.966</td>
<td>131.6 ± 4.588</td>
</tr>
<tr>
<td/>
<td>1</td>
<td>52.47 ± 1.746</td>
<td>131.2 ± 6.022</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881112466182"><p>Data presented as mean ± s.e.m, <italic>n</italic>=18 animals per group, within-subject, *<italic>p</italic>&lt;0.05 versus vehicle. Abbreviations: csec, centiseconds.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-0269881112466182">
<title>Experiment 2: Effects of the SSRIs, fluoxetine, citalopram and paroxetine on performance in the 5-CSRTT</title>
<p>Premature responses were significantly reduced by fluoxetine (0.1–3.0 mg/kg i.p.) [<italic>F</italic> (3.7, 63.3)=5.166, <italic>p</italic>=0.001], citalopram (0.1–3.0 mg/kg, i.p.) [<italic>F</italic> (3.4, 58.0)=2.321, <italic>p</italic>=0.014] and paroxetine (0.3–3.0 mg/kg, i.p.) [<italic>F</italic> (1.7, 29.4)=16.36, <italic>p</italic>&lt;0.0001] treatment. Paroxetine reduced premature responses at all the doses tested, whilst citalopram and fluoxetine only reduced premature responses at the higher doses tested.</p>
<p>Fluoxetine did not have any effect on accuracy [<italic>F</italic> (4.0, 67.9)=0.259, <italic>p</italic>=0.90] but significantly increased omissions [<italic>F</italic> (3.6, 61.4)=5.920, <italic>p</italic>=0.001] at the highest dose. Correct latency [<italic>F</italic> (4.0, 68.0)=7.130, <italic>p</italic>&lt;0.0001] and collection latency [<italic>F</italic> (2.8, 47.9)=5.490, <italic>p</italic>=0.003] were also significantly increased at the highest dose. Accuracy was not affected by paroxetine [<italic>F</italic> (2.6, 44.6)=2.183, <italic>p</italic>=0.11]; nevertheless, it induced a significant increase in omitted responses [<italic>F</italic> (1.6, 27.2)=14.908, <italic>p</italic>&lt;0.0001], correct latency [<italic>F</italic> (2.8, 48.0)=12.582, <italic>p</italic>&lt;0.0001] and collection latency [<italic>F</italic> (2.2, 36.9)=8.227, <italic>p</italic>=0.001], but only at the highest dose tested. Citalopram did not significantly affect accuracy [<italic>F</italic> (3.7, 62.3)=0.236, <italic>p</italic>=0.90] or omitted responses [<italic>F</italic> (2.0, 34.0)=1.671, <italic>p</italic>=0.20]. However, it significantly increased correct latency [<italic>F</italic> (3.9, 65.5)=5.192, <italic>p</italic>=0.01] and tended to increase collection latency [<italic>F</italic> (2.5, 41.8)=2.902, <italic>p</italic>=0.06]. Results are shown in <xref ref-type="fig" rid="fig2-0269881112466182">Figure 2</xref> and <xref ref-type="table" rid="table1-0269881112466182">Table 1</xref>.</p>
<fig id="fig2-0269881112466182" position="float">
<label>Figure 2.</label>
<caption>
<p>Effects of serotonin specific reuptake inhibitors, fluoxetine (0.0–3.0 mg/kg, i.p), citalopram (0.0–3.0 mg/kg, i.p) and paroxetine (0.0–3.0 mg/kg, i.p.) on the percent correct, omission and premature responses (<italic>n</italic>=18). Data shown as mean ± s.e. mean. * denotes <italic>p</italic>&lt;0.05 compared with vehicle treatment.</p>
</caption>
<graphic xlink:href="10.1177_0269881112466182-fig2.tif"/></fig>
</sec>
<sec id="section11-0269881112466182">
<title>Experiment 3: Effects of idazoxan and agomelatine on performance in the 5-CSRTT</title>
<p>Neither idazoxan (0.3–3.0 mg/kg, i.p.) nor agomelatine (0.1–1.0 mg/kg, i.p.) had any significant effects on premature responses, accuracy or omissions (<italic>F</italic>&lt;1.6, <italic>p</italic>&gt;0.29). Idazoxan significantly increased correct latency [<italic>F</italic> (3.0, 51.0)=3.602, <italic>p</italic>=0.02] and tended to increase collection latency [<italic>F</italic> (3.0, 51.0)=1.170, <italic>p</italic>=0.06], whilst agomelatine had no effect on latencies (<italic>F</italic>&lt;1.3, <italic>p</italic>&gt;0.88). Results are presented in <xref ref-type="fig" rid="fig3-0269881112466182">Figure 3</xref> and <xref ref-type="table" rid="table1-0269881112466182">Table 1</xref>.</p>
<fig id="fig3-0269881112466182" position="float">
<label>Figure 3.</label>
<caption>
<p>Effects of the alpha2-adrenoceptor antagonist, idazoxan (0.0–3.0 mg/kg, i.p.) and melatonergic agonist and 5-HT2C antagonist, agomelatine (0.0–1.0 mg/kg, i.p.) on the percent correct, omission and premature responses (<italic>n</italic>=18). Data shown as mean ± s.e. mean. * denotes <italic>p</italic>&lt;0.05 compared with vehicle treatment.</p>
</caption>
<graphic xlink:href="10.1177_0269881112466182-fig3.tif"/></fig>
</sec>
</sec>
<sec id="section12-0269881112466182" sec-type="discussion">
<title>Discussion</title>
<p>Taken together, these data suggest that drugs which bind to the noradrenaline and serotonin transporters have beneficial effects on impulse control. The results obtained with venlafaxine reveal that this antidepressant specifically improved the control of impulsive action, an effect which may involve its affinity for both noradrenaline and 5-HT reuptake sites. The mixed SNRI sibutramine tended to show a similar profile, although the effects on premature responses were not significant. All three of the SSRIs reduced premature responding in rats, although only paroxetine appeared to specifically reduce this variable, with both fluoxetine and citalopram also affecting response and collection latencies. Of the three SSRIs tested, paroxetine is thought to be the most potent at the noradrenaline transporter, which may contribute to the effects observed here (<xref ref-type="bibr" rid="bibr7-0269881112466182">Béïque et al., 1998</xref>). The higher doses of all these compounds caused non-specific effects indicative of effects on motivation (<xref ref-type="bibr" rid="bibr59-0269881112466182">Robbins, 2002</xref>). Increasing noradrenaline levels through non-reuptake mechanisms and the mixed noradrenaline and dopamine re-uptake inhibitor did not improve impulse control. At the doses of idazoxan tested, in vivo microdialysis studies have shown an increase in noradrenaline and dopamine levels in the frontal cortex (<xref ref-type="bibr" rid="bibr10-0269881112466182">Bengtsson et al., 2000</xref>; <xref ref-type="bibr" rid="bibr24-0269881112466182">Devoto et al., 2001</xref>) but lacked efficacy in this study. The doses of agomelatine were relatively low compared with microdialysis studies (<xref ref-type="bibr" rid="bibr47-0269881112466182">Millan et al., 2003</xref>) and thus may have been insufficient.</p>
<sec id="section13-0269881112466182">
<title>Effects of mixed action monoamine reuptake inhibitors on impulsive responding in the 5-CSRTT</title>
<p>Venlafaxine decreased premature responding and increased correct latency in a dose-dependent manner without affecting any other variables. These data suggest that this SNRI reduces motivation to respond to the stimulus but without a generalised motor deficit or affecting motivation to collect the reward. Affinity for the noradrenaline reuptake site may mediate these effects. Neurochemical studies have shown that acute venlafaxine treatment induced rapid noradrenaline release in the frontal cortex higher than 5-HT release (<xref ref-type="bibr" rid="bibr23-0269881112466182">Dawson et al., 1999</xref>), although more recently it is thought to have a 30-fold higher affinity for 5-HTT compared with that for noradrenaline transporter (NAT) (<xref ref-type="bibr" rid="bibr66-0269881112466182">Stahl et al., 2005</xref>). A role for the NAT in these effects is in keeping with the efficacy of noradrenergic agents in treating impulse control disorders (<xref ref-type="bibr" rid="bibr49-0269881112466182">Navarra et al., 2008</xref>) and their effects in animal studies (for example see <xref ref-type="bibr" rid="bibr13-0269881112466182">Blondeau and Dellu-Hagedorn, 2006</xref>; <xref ref-type="bibr" rid="bibr29-0269881112466182">Floresco and Jentsch 2011</xref>, <xref ref-type="bibr" rid="bibr61-0269881112466182">Robinson et al., 2008a</xref>).</p>
<p>A similar effect would be predicted for sibutramine, given its affinity at the noradrenaline and 5-HT transporters (<xref ref-type="bibr" rid="bibr43-0269881112466182">Luscombe et al., 1989</xref>). In this study, sibutramine reduced premature responses by ~50%, although the level of premature responses recorded under saline conditions were lower than for other studies, which may have limited our ability to detect a significant change. Overall, premature responding across this study was low. Further studies, particularly with sibutramine, in a modified version of the task, such as a variable ITI or long ITI (<xref ref-type="bibr" rid="bibr59-0269881112466182">Robbins, 2002</xref>), which increases baseline levels of anticipatory responses, would be useful. The lack of effect with sibutramine may also be influenced by pharmacokinetic factors, as it is the active metabolite of sibutramine which acts at the transporters (<xref ref-type="bibr" rid="bibr36-0269881112466182">Heal et al., 1998</xref>) and the 40 min post-treatment testing may not have allowed sufficient time for a maximal effect to be observed.</p>
<p>Considering the neurochemical data relating to both the SNRIs and SSRIs used in this study, the ability of the drug to elevate cortical noradrenaline appears to be important. Both venlafaxine and sibutramine elevate noradrenaline and serotonin through their mixed action at the re-uptake sites. These drugs may also increase cortical dopamine in a similar manner to the NRI, atomoxetine (<xref ref-type="bibr" rid="bibr67-0269881112466182">Swanson et al., 2006</xref>). In studies using microdialysis, a dose of 10 mg/kg venlafaxine had a much greater effect on cortical noradrenaline compared with serotonin (<xref ref-type="bibr" rid="bibr12-0269881112466182">Beyer et al., 2002</xref>), which may underlie its efficacy in this study. However, given the reduction in premature responses also observed with the SSRIs in this study, venlafaxine effects may involve its binding to both noradrenaline and serotonin transporters.</p>
<p>We also found that the mixed NAT and dopamine transporter inhibitor bupropion had no significant effects in the 5-CSRTT at the doses tested. Previous studies have found a similar lack of efficacy in the stop task, and the delay and probability discounting task (<xref ref-type="bibr" rid="bibr1-0269881112466182">Acheson and de Wit, 2008</xref>). Bupropion increases both noradrenaline and dopamine concentrations (<xref ref-type="bibr" rid="bibr17-0269881112466182">Carroll et al., 2009</xref>), therefore the effect at the NAT may be counteracted by enhanced dopamine, which has been shown to increase premature responding in this task. The dopaminergic reuptake inhibitor GBR-12909 increased impulsivity in the 5-CSRTT, and the psychostimulant methylphenidate has been shown to have mixed effects depending on route of administration and dose (<xref ref-type="bibr" rid="bibr4-0269881112466182">Baarendse and Vanderschuren, 2012</xref>; <xref ref-type="bibr" rid="bibr13-0269881112466182">Blondeau and Dellu-Hagedorn, 2006</xref>; <xref ref-type="bibr" rid="bibr28-0269881112466182">Fernando et al., 2012</xref>; <xref ref-type="bibr" rid="bibr48-0269881112466182">Milstein et al., 2010</xref>; <xref ref-type="bibr" rid="bibr51-0269881112466182">Paine et al., 2007</xref>; <xref ref-type="bibr" rid="bibr52-0269881112466182">Paterson et al. 2011</xref>; <xref ref-type="bibr" rid="bibr54-0269881112466182">Pattij et al., 2012</xref>; <xref ref-type="bibr" rid="bibr60-0269881112466182">Robinson, 2012</xref>; <xref ref-type="bibr" rid="bibr77-0269881112466182">Van Gaalen et al., 2006</xref>). For example, <xref ref-type="bibr" rid="bibr48-0269881112466182">Milstein et al. (2010)</xref> found that methylphenidate increased impulsivity, whilst <xref ref-type="bibr" rid="bibr60-0269881112466182">Robinson (2012)</xref> found low oral doses reduced premature responding. These seeming contradictory results are thought to reflect the fact that low oral doses are relatively specific to cortical catecholamines (<xref ref-type="bibr" rid="bibr11-0269881112466182">Berridge et al., 2006</xref>).</p>
</sec>
<sec id="section14-0269881112466182">
<title>Effects of SSRIs on impulsive responding in the 5-CSRTT</title>
<p>The hypothesis that 5-HT hypofunction is linked to increased impulsive behaviour has been reported for many years (<xref ref-type="bibr" rid="bibr41-0269881112466182">Linnoila et al. 1983</xref>; <xref ref-type="bibr" rid="bibr65-0269881112466182">Soubrié, 1986</xref>), including evidence from animal studies (for review see <xref ref-type="bibr" rid="bibr35-0269881112466182">Harrison et al., 1997</xref>; <xref ref-type="bibr" rid="bibr59-0269881112466182">Robbins, 2002</xref>). Although 5-HT is thought to be the ‘brake’ on impulsive behaviour, findings in the present study showed that this was only specific in the case for paroxetine, with the highest dose for fluoxetine and citalopram reducing premature responses but also affecting omissions and both response and collection latencies, suggesting more general effects on motivation. Previous studies investigating SSRIs in the 5-CSRTT have also shown reductions in premature responses. <xref ref-type="bibr" rid="bibr4-0269881112466182">Baarendse and Vanderschuren (2012)</xref> found a specific reduction in premature responding following treatment with citalopram, but <xref ref-type="bibr" rid="bibr69-0269881112466182">Tsutsui-Kimura et al. (2009)</xref> failed to find any effects with fluvoxamine in terms of premature responses, but did find deficits in accuracy and omissions at the highest dose tested.</p>
<p>The results from the present study suggest that SSRI administration can reduce premature responding in the 5-CSRTT but, for most of the SSRIs tested, these effects may be secondary to effects on motivation to perform the task. Although the SSRIs are broadly considered to be selective for the serotonin transporter, in vivo microdialysis studies have shown that some but not all SSRIs also increase cortical noradrenaline (for example see <xref ref-type="bibr" rid="bibr12-0269881112466182">Beyer et al., 2002</xref>; <xref ref-type="bibr" rid="bibr34-0269881112466182">Hajos-Korcsok et al., 2000</xref>; <xref ref-type="bibr" rid="bibr39-0269881112466182">Jordan et al., 1994</xref>; <xref ref-type="bibr" rid="bibr68-0269881112466182">Thomas et al., 1998</xref>; <xref ref-type="bibr" rid="bibr80-0269881112466182">Zhang et al., 2000</xref>). Pertinent to our observations are data suggesting that paroxetine but not fluoxetine increased cortical noradrenaline (<xref ref-type="bibr" rid="bibr12-0269881112466182">Beyer et al., 2002</xref>; <xref ref-type="bibr" rid="bibr46-0269881112466182">Millan et al., 1999</xref>). A study by <xref ref-type="bibr" rid="bibr46-0269881112466182">Millan et al. (1999)</xref> also failed to find any effect following acute treatment with citalopram. However, not all studies have found similar effects, with other studies reporting no increase in noradrenaline following treatment with paroxetine (<xref ref-type="bibr" rid="bibr34-0269881112466182">Hajos-Korcsok et al., 2000</xref>), whilst fluoxetine was shown to increase cortical noradrenaline (<xref ref-type="bibr" rid="bibr15-0269881112466182">Bymaster et al., 2002</xref>). In vitro studies have also shown that paroxetine has moderate affinity for the NAT (<xref ref-type="bibr" rid="bibr7-0269881112466182">Béïque et al., 1998</xref>). Studies in patients also indicate that significant noradrenaline re-uptake inhibition occurred following paroxetine administration, an effect which is hypothesised to contribute to its antidepressant and anxiolytic efficacy (<xref ref-type="bibr" rid="bibr31-0269881112466182">Gilmor et al., 2002</xref>). Given our previous findings with atomoxetine (<xref ref-type="bibr" rid="bibr61-0269881112466182">Robinson et al., 2008a</xref>) and the results from the present investigation relating to the efficacy of venlafaxine, the higher affinity of paroxetine for the NAT may account for the effects observed here.</p>
<p>The increase in omissions and response latencies observed at the higher doses may involve central effects on appetite and/or gastrointestinal disturbance arising from periphery increases in serotonin. These data are potentially relevant to understanding the lack of efficacy of SSRIs in ADHD. Our results do not indicate SSRIs have any detrimental effects on impulsive action which could contribute to increased suicide attempts (<xref ref-type="bibr" rid="bibr38-0269881112466182">Javdani et al., 2011</xref>). This study has only examined acute effects of these drugs, and changes in impulse control following chronic administration may also occur. Long-term administration of monoamine re-uptake inhibitors induces a number of neuroadaptive changes (<xref ref-type="bibr" rid="bibr8-0269881112466182">Bel and Artigas, 1999</xref>; <xref ref-type="bibr" rid="bibr64-0269881112466182">Rutter et al., 1995</xref>) which may have effects on impulse control as well as influencing the response to subsequent acute doses of the drug.</p>
</sec>
<sec id="section15-0269881112466182">
<title>Effects of idazoxan and agomelatine on impulsive responding in the 5-CSRTT</title>
<p>Neither agomelatine nor idazoxan had a significant effect on premature responding. Treatment with idazoxan should increase cortical noradrenaline and dopamine to a level similar to that achieved through NAT inhibition; however, the lack of benefit on impulse control suggests that these raised catecholamines are not sufficient to replicate the effects of a NRI, such as atomoxetine. These data suggest that the mechanisms by which NRIs exert their effects are specific to their actions at the noradrenaline transporter and may not be an effect common to other treatments which increase cortical catecholamines through non-reuptake mechanisms. One potential issue with using idazoxan is that it will also have antagonist effects on post-synaptic alpha2-adrenoceptors. <xref ref-type="bibr" rid="bibr42-0269881112466182">Liu et al. (2009)</xref> found a similar lack of effect in the 5-CSRTT using the selective alpha2-adrenoceptor antagonist RX821002. These receptors have been proposed as a key target through which noradrenaline mediates its beneficial effects on impulse control (<xref ref-type="bibr" rid="bibr3-0269881112466182">Arnsten and Dudley, 2005</xref>). Previous studies using the 5-CSRTT have also shown that alpha2-adrenoceptor agonists improve impulse control in this task (<xref ref-type="bibr" rid="bibr28-0269881112466182">Fernando et al., 2012</xref>; <xref ref-type="bibr" rid="bibr54-0269881112466182">Pattij et al., 2012</xref>), although these drugs tend to have effects on other variables at higher doses as well. Other studies suggest that the beta adrenoceptor is an important modulator of impulse control in the 5-CSRTT. <xref ref-type="bibr" rid="bibr48-0269881112466182">Milstein et al. (2010)</xref> found that beta adrenoceptor antagonists blocked impulsive responses induced by methylphenidate, whilst <xref ref-type="bibr" rid="bibr54-0269881112466182">Pattij et al. (2012)</xref> found that a selective beta2-adrenoceptor agonist reduced premature responding specifically.</p>
<p>Agomelatine exerts its main therapeutic effects by acting as an agonist at melatonin (MT<sub>1</sub> and MT<sub>2</sub>) receptors and as an antagonist at 5-HT<sub>2C</sub> receptors. Its effects at 5-HT<sub>2C</sub> receptors are thought to lead to increases in noradrenaline and dopamine in regions such as the prefrontal cortex (<xref ref-type="bibr" rid="bibr47-0269881112466182">Millan et al., 2003</xref>). 5-HT<sub>2C</sub> antagonists have also been shown to increase impulsive responding in the 5-CSRTT following both systemic (<xref ref-type="bibr" rid="bibr75-0269881112466182">Winstanley et al., 2004</xref>) and local administration (<xref ref-type="bibr" rid="bibr62-0269881112466182">Robinson et al., 2008b</xref>). Despite evidence that agomelatine increases noradrenaline and dopamine in cortical brain areas (<xref ref-type="bibr" rid="bibr47-0269881112466182">Millan et al., 2003</xref>), the lack of effects in these studies suggest that it does not lead to any beneficial or detrimental effects on attention and impulse control in this model. This may be due to the competing mechanisms of increased cortical noradrenaline and dopamine enhancing impulse control versus 5-HT<sub>2C</sub> antagonism impairing impulse control. However, the doses used in this study were lower than those previously reported for in vivo microdialysis studies, and therefore these results may reflect only limited effects on cortical catecholamines.</p>
</sec>
<sec id="section16-0269881112466182">
<title>Effects on attentional performance in the 5-CSRTT</title>
<p>None of the drugs tested significantly improved choice accuracy in the 5-CSRTT, suggesting these manipulations to monoamine transmitters did not alter attentional performance in this task. Previous studies using atomoxetine have found attentional improvements in a modified 5-CSRTT (<xref ref-type="bibr" rid="bibr60-0269881112466182">Robinson, 2012</xref>), whilst dopamine reuptake inhibitors and treatment with stimulant drugs tend to worsen attention (for example see <xref ref-type="bibr" rid="bibr4-0269881112466182">Baarendse and Vanderschuren, 2012</xref>). SSRIs have not previously been shown to improve attention in the 5-CSRTT, although depleting 5-HT from forebrain regions does induce detrimental effects on attentional accuracy (<xref ref-type="bibr" rid="bibr16-0269881112466182">Carli and Samanin, 1992</xref>; <xref ref-type="bibr" rid="bibr35-0269881112466182">Harrison et al., 1997</xref>; <xref ref-type="bibr" rid="bibr37-0269881112466182">Jäkälä et al., 1992</xref>; <xref ref-type="bibr" rid="bibr57-0269881112466182">Puumala and Sirviö, 1998</xref>; <xref ref-type="bibr" rid="bibr75-0269881112466182">Winstanley et al., 2004</xref>). The lack of effects on attention may also be due to the high baseline level of performance (~90% accuracy) resulting in a ceiling effect. Non-specific effects on general engagement with the task were observed, with sibutramine, fluoxetine and citalopram increasing omissions at the highest doses tested, and paroxetine tended to also increase the number of omitted trials. In most cases, this increase in omissions was associated with increases in latency to collect the reward, suggesting a general deficit in motivation rather than any specific effects on visuo-spatial attention.</p>
<p>Although these data suggest an important role for the noradrenaline transporter and cortical noradrenaline in impulse control, several caveats should be taken into consideration when interpreting these data. Firstly, it is important to consider the doses used in this study and the fact that plasma levels of the drugs and receptor occupancy data were not obtained. Without this information, we cannot be absolutely sure about the site of action of these drugs, although their specific effects are in keeping with doses likely to affect their primary target. Most of the drugs tested are reuptake inhibitors and will increase neurotransmission only after they have accumulated in the synapse. The time point used in these studies may not have been sufficient for maximal effects on synaptic concentrations. Studies have also suggested that acute treatment with SSRIs leads to a reduction in serotonin release involving effects on 5-HT autoreceptors (<xref ref-type="bibr" rid="bibr8-0269881112466182">Bel and Artigas, 1999</xref>; <xref ref-type="bibr" rid="bibr64-0269881112466182">Rutter et al., 1995</xref>), an effect which may account for reasons why the SNRIs and some SSRIs affect cortical noradrenaline to a greater extent than cortical serotonin. Finally, these studies used normal animals, and it is not known what effects these drugs may have in pathological states, particularly where different baseline levels of monoaminergic tone exist. Further studies using an animal model of ADHD such as the spontaneously hypertensive rat could address these issues.</p>
<p>In summary, the findings of the current study suggest that treatment of impulse control disorders could include drugs which inhibit the reuptake of both noradrenaline and serotonin. This may be useful when treating impulse control disorders where affective symptoms are also present, for example borderline personality disorder. A dual-action drug could have better efficacy than an SSRI or a NRI alone. Indeed, there is some evidence supporting the efficacy of SNRIs (venlafaxine and duloxetine) in borderline personality disorder (<xref ref-type="bibr" rid="bibr9-0269881112466182">Bellino et al., 2010</xref>; <xref ref-type="bibr" rid="bibr45-0269881112466182">Markovitz and Wagner, 1995</xref>). In relation to SSRI-induced increases in impulsive behaviour and a possible link with increased risk of suicidal behaviour, the present study does not provide any evidence to suggest that SSRIs increase impulsive action. It seems unlikely that any increase in suicide risk associated with SSRI treatment involves direct effects on the form of impulse action measured in this task.</p>
</sec>
</sec>
</body>
<back>
<ack><p>Clara Humpston carried out some of the work described in this paper during her final year research project which contributed to her BSc (Hons) Pharmacology. The authors would like to thank Sian Cundy for technical assistance.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>Funding for this research was provided by a Medical Research Council New Investigator grant (Ref: G0700980) awarded to E.S.J.R.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors of this manuscript have no conflict of interests. Funding for this research was provided by a Medical Research Council New Investigator grant (Ref: G0700980) awarded to E.S.J.R.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Acheson</surname><given-names>A</given-names></name>
<name><surname>de Wit</surname><given-names>H</given-names></name>
</person-group> (<year>2008</year>) <article-title>Bupropion improves attention but does not affect impulsive behaviour in healthy young adults</article-title>. <source>Exp Clin Psychopharmacol</source> <volume>16</volume>: <fpage>113</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr2-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnsten</surname><given-names>AF</given-names></name>
</person-group> (<year>2006</year>) <article-title>Stimulants: Therapeutic actions in ADHD</article-title>. <source>Neuropsychopharmacology</source> <volume>31</volume>: <fpage>2376</fpage>–<lpage>2383</lpage>.</citation>
</ref>
<ref id="bibr3-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnsten</surname><given-names>AF</given-names></name>
<name><surname>Dudley</surname><given-names>AG</given-names></name>
</person-group> (<year>2005</year>) <article-title>Methylphenidate improves prefrontal cortical cognitive function through alpha2-adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder</article-title>. <source>Behav Brain Func</source> <volume>1</volume>: <fpage>2</fpage>.</citation>
</ref>
<ref id="bibr4-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baarendse</surname><given-names>PJ</given-names></name>
<name><surname>Vanderschuren</surname><given-names>LJ</given-names></name>
</person-group> (<year>2012</year>) <article-title>Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats</article-title>. <source>Psychopharmacology (Berl)</source> <volume>219</volume>: <fpage>313</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr5-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bari</surname><given-names>A</given-names></name>
<name><surname>Dalley</surname><given-names>JW</given-names></name>
<name><surname>Robbins</surname><given-names>TW</given-names></name>
</person-group> (<year>2008</year>) <article-title>The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats</article-title>. <source>Nat Protoc</source> <volume>3</volume>: <fpage>759</fpage>–<lpage>767</lpage>.</citation>
</ref>
<ref id="bibr6-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bari</surname><given-names>A</given-names></name>
<name><surname>Eagle</surname><given-names>DM</given-names></name>
<name><surname>Mar</surname><given-names>AC</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats</article-title>. <source>Psychopharmacology (Berl)</source> <volume>205</volume>: <fpage>273</fpage>–<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr7-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Béïque</surname><given-names>JC</given-names></name>
<name><surname>Lavoie</surname><given-names>N</given-names></name>
<name><surname>de Montigny</surname><given-names>C</given-names></name>
<etal/></person-group>. (<year>1998</year>) <article-title>Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters</article-title>. <source>Eur J Pharmacol</source> <volume>349</volume>: <fpage>129</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr8-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bel</surname><given-names>N</given-names></name>
<name><surname>Artigas</surname><given-names>F</given-names></name>
</person-group> (<year>1999</year>) <article-title>Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats</article-title>. <source>Neuropsychopharmacology</source> <volume>21</volume>: <fpage>745</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr9-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bellino</surname><given-names>S</given-names></name>
<name><surname>Paradiso</surname><given-names>E</given-names></name>
<name><surname>Bozzatello</surname><given-names>P</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study</article-title>. <source>J Psychopharmacol</source> <volume>24</volume>: <fpage>333</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr10-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bengtsson</surname><given-names>HJ</given-names></name>
<name><surname>Kele</surname><given-names>J</given-names></name>
<name><surname>Johansson</surname><given-names>J</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source> <volume>362</volume>: <fpage>406</fpage>–<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr11-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berridge</surname><given-names>CW</given-names></name>
<name><surname>Devilbiss</surname><given-names>DM</given-names></name>
<name><surname>Andrzejewski</surname><given-names>ME</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function</article-title>. <source>Biol Psychiatry</source> <volume>60</volume>: <fpage>1111</fpage>–<lpage>1120</lpage>.</citation>
</ref>
<ref id="bibr12-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beyer</surname><given-names>CE</given-names></name>
<name><surname>Boikess</surname><given-names>S</given-names></name>
<name><surname>Luo</surname><given-names>B</given-names></name>
<etal/></person-group>. (<year>2002</year>) <article-title>Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study</article-title>. <source>J Psychopharmacol</source> <volume>16</volume>: <fpage>297</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr13-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blondeau</surname><given-names>C</given-names></name>
<name><surname>Dellu-Hagedorn</surname><given-names>F</given-names></name>
</person-group> (<year>2006</year>) <article-title>Dimensional analysis of ADHD subtypes in rats</article-title>. <source>Biol Psychiatry</source> <volume>61</volume>: <fpage>1340</fpage>–<lpage>1350</lpage>.</citation>
</ref>
<ref id="bibr14-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braquehais</surname><given-names>MD</given-names></name>
<name><surname>Ramos-Quiroga</surname><given-names>JA</given-names></name>
<name><surname>Sher</surname><given-names>L</given-names></name>
</person-group> (<year>2010</year>) <article-title>Impulsivity: current and future trends in pharmacological treatment</article-title>. <source>Exp Rev Neurother</source> <volume>10</volume>: <fpage>1367</fpage>–<lpage>1369</lpage>.</citation>
</ref>
<ref id="bibr15-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bymaster</surname><given-names>FP</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Carter</surname><given-names>PA</given-names></name>
<etal/></person-group>. (<year>2002</year>) <article-title>Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex</article-title>. <source>Psychopharmacology (Berl)</source> <volume>160</volume>: <fpage>353</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr16-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carli</surname><given-names>M</given-names></name>
<name><surname>Samanin</surname><given-names>R</given-names></name>
</person-group> (<year>1992</year>) <article-title>Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats’ performance differently in a five-choice serial reaction time task</article-title>. <source>Psychopharmacology (Berl)</source> <volume>106</volume>: <fpage>228</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr17-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carroll</surname><given-names>FI</given-names></name>
<name><surname>Blough</surname><given-names>BE</given-names></name>
<name><surname>Abraham</surname><given-names>P</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction</article-title>. <source>J Med Chem</source> <volume>52</volume>: <fpage>6768</fpage>–<lpage>6781</lpage>.</citation>
</ref>
<ref id="bibr18-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chamberlain</surname><given-names>SR</given-names></name>
<name><surname>Sahakian</surname><given-names>BJ</given-names></name>
</person-group> (<year>2007</year>) <article-title>The neuropsychiatry of impulsivity</article-title>. <source>Curr Opin Psychiatry</source> <volume>20</volume>: <fpage>255</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr19-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chamberlain</surname><given-names>SR</given-names></name>
<name><surname>Muller</surname><given-names>U</given-names></name>
<name><surname>Blackwell</surname><given-names>AD</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Neurochemical modulation of response inhibition and probabilistic learning in humans</article-title>. <source>Science</source> <volume>311</volume>: <fpage>861</fpage>–<lpage>863</lpage>.</citation>
</ref>
<ref id="bibr20-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dalley</surname><given-names>JW</given-names></name>
<name><surname>Cardinal</surname><given-names>RN</given-names></name>
<name><surname>Robbins</surname><given-names>TW</given-names></name>
</person-group> (<year>2004</year>) <article-title>Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates</article-title>. <source>Neurosci Biobehav Rev</source> <volume>28</volume>: <fpage>771</fpage>–<lpage>784</lpage>.</citation>
</ref>
<ref id="bibr21-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dalley</surname><given-names>JW</given-names></name>
<name><surname>Everitt</surname><given-names>BJ</given-names></name>
<name><surname>Robbins</surname><given-names>TW</given-names></name>
</person-group> (<year>2011</year>) <article-title>Impulsivity, compulsivity, and top-down cognitive control</article-title>. <source>Neuron</source> <volume>69</volume>: <fpage>680</fpage>–<lpage>694</lpage>.</citation>
</ref>
<ref id="bibr22-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dalley</surname><given-names>JW</given-names></name>
<name><surname>Mar</surname><given-names>AC</given-names></name>
<name><surname>Economidou</surname><given-names>D</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry</article-title>. <source>Pharmacol Biochem Behav</source> <volume>90</volume>: <fpage>250</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr23-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawson</surname><given-names>LA</given-names></name>
<name><surname>Nguyen</surname><given-names>HQ</given-names></name>
<name><surname>Geiger</surname><given-names>A</given-names></name>
</person-group> (<year>1999</year>) <article-title>Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism</article-title>. <source>Neuropharmacology</source> <volume>38</volume>: <fpage>1153</fpage>–<lpage>1163</lpage>.</citation>
</ref>
<ref id="bibr24-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Devoto</surname><given-names>P</given-names></name>
<name><surname>Flore</surname><given-names>G</given-names></name>
<name><surname>Pani</surname><given-names>L</given-names></name>
<etal/></person-group>. (<year>2001</year>) <article-title>Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex</article-title>. <source>Mol Psychiatry</source> <volume>6</volume>: <fpage>657</fpage>–<lpage>664</lpage>.</citation>
</ref>
<ref id="bibr25-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eagle</surname><given-names>DM</given-names></name>
<name><surname>Baunez</surname><given-names>C</given-names></name>
</person-group> (<year>2010</year>) <article-title>Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition</article-title>. <source>Neurosci Biobehav Rev</source> <volume>34</volume>: <fpage>50</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr26-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Evenden</surname><given-names>JL</given-names></name>
</person-group> (<year>1999a</year>). <article-title>Varieties of impulsivity</article-title>. <source>Psychopharmacology (Berl)</source> <volume>146</volume>: <fpage>348</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr27-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Evenden</surname><given-names>JL</given-names></name>
</person-group> (<year>1999b</year>). <article-title>Impulsivity: a discussion of clinical and experimental findings</article-title>. <source>J Psychopharmacol</source> <volume>13</volume>: <fpage>180</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr28-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fernando</surname><given-names>AB</given-names></name>
<name><surname>Economidou</surname><given-names>D</given-names></name>
<name><surname>Theobald</surname><given-names>DE</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists</article-title>. <source>Psychopharmacology (Berl)</source> <volume>219</volume>: <fpage>341</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr29-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Floresco</surname><given-names>SB</given-names></name>
<name><surname>Jentsch</surname><given-names>JD</given-names></name>
</person-group> (<year>2011</year>) <article-title>Pharmacological enhancement of memory and executive functioning in laboratory animals</article-title>. <source>Neuropsychopharmacology</source> <volume>36</volume>: <fpage>227</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr30-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fone</surname><given-names>KC</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>2005</year>) <article-title>Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder</article-title>. <source>Curr Opin Pharmacol</source> <volume>5</volume>: <fpage>87</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr31-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gilmor</surname><given-names>ML</given-names></name>
<name><surname>Owens</surname><given-names>MJ</given-names></name>
<name><surname>Nemeroff</surname><given-names>CB</given-names></name>
</person-group> (<year>2002</year>) <article-title>Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine</article-title>. <source>Am J Psychiatry</source> <volume>159</volume>: <fpage>1702</fpage>–<lpage>1710</lpage>.</citation>
</ref>
<ref id="bibr32-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gundlah</surname><given-names>C</given-names></name>
<name><surname>Martin</surname><given-names>KF</given-names></name>
<name><surname>Heal</surname><given-names>DJ</given-names></name>
<etal/></person-group>. (<year>1997</year>) <article-title>In vivo criteria to differentiate monoamine uptake inhibitors from releasing drugs: Sibutramine is a reuptake inhibitor</article-title>. <source>J Pharmacol Exp Ther</source> <volume>283</volume>: <fpage>581</fpage>–<lpage>591</lpage>.</citation>
</ref>
<ref id="bibr33-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gvion</surname><given-names>Y</given-names></name>
<name><surname>Apter</surname><given-names>A</given-names></name>
</person-group> (<year>2011</year>) <article-title>Aggression, impulsivity, and suicide behaviour: a review of the literature</article-title>. <source>Arch Suicide Res</source> <volume>15</volume>: <fpage>93</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr34-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hajos-Korcsok</surname><given-names>E</given-names></name>
<name><surname>McTavish</surname><given-names>SFB</given-names></name>
<name><surname>Sharp</surname><given-names>T</given-names></name>
</person-group> (<year>2000</year>) <article-title>Effect of a selective 5- hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine</article-title>. <source>Eur J Pharmacol</source> <volume>407</volume>: <fpage>101</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr35-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>AA</given-names></name>
<name><surname>Everitt</surname><given-names>BJ</given-names></name>
<name><surname>Robbins</surname><given-names>TW</given-names></name>
</person-group> (<year>1997</year>) <article-title>Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms</article-title>. <source>Psychopharmacology (Berl)</source> <volume>133</volume>: <fpage>329</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr36-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heal</surname><given-names>DJ</given-names></name>
<name><surname>Aspley</surname><given-names>S</given-names></name>
<name><surname>Prow</surname><given-names>MR</given-names></name>
<etal/></person-group>. (<year>1998</year>) <article-title>Sibutramine: a novel anti- obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine</article-title>. <source>Int J Obes Relat Metab Disord</source> <volume>22</volume>(<supplement>Suppl 1</supplement>): <fpage>S18</fpage>–<lpage>S28</lpage>.</citation>
</ref>
<ref id="bibr37-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jäkälä</surname><given-names>P</given-names></name>
<name><surname>Sirviö</surname><given-names>J</given-names></name>
<name><surname>Jolkkonen</surname><given-names>J</given-names></name>
<etal/></person-group>. (<year>1992</year>) <article-title>The effects of p-chlorophenylalanine-induced serotonin synthesis inhibition and muscarinic blockade on the performance of rats in a 5-choice serial reaction time task</article-title>. <source>Behav Brain Res</source> <volume>51</volume>: <fpage>29</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr38-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Javdani</surname><given-names>S</given-names></name>
<name><surname>Sadeh</surname><given-names>N</given-names></name>
<name><surname>Verona</surname><given-names>E</given-names></name>
</person-group> (<year>2011</year>) <article-title>Suicidality as a function of impulsivity, callous-unemotional traits, and depressive symptoms in youth</article-title>. <source>J Abnorm Psychol</source> <volume>120</volume>: <fpage>400</fpage>–<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr39-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jordan</surname><given-names>S</given-names></name>
<name><surname>Kramer</surname><given-names>G L</given-names></name>
<name><surname>Zukas</surname><given-names>PK</given-names></name>
<etal/></person-group>. (<year>1994</year>) <article-title>In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine</article-title>. <source>Synapse</source> <volume>18</volume>: <fpage>294</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr40-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kamali</surname><given-names>M</given-names></name>
<name><surname>Oquendo</surname><given-names>MA</given-names></name>
<name><surname>Mann</surname><given-names>JJ</given-names></name>
</person-group> (<year>2001</year>) <article-title>Understanding the neurobiology of suicidal behavior</article-title>. <source>Depress Anxiety</source> <volume>14</volume>: <fpage>164</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr41-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Linnoila</surname><given-names>M</given-names></name>
<name><surname>Virkkunen</surname><given-names>M</given-names></name>
<name><surname>Scheinin</surname><given-names>M</given-names></name>
<etal/></person-group>. (<year>1983</year>) <article-title>Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior</article-title>. <source>Life Sci</source> <volume>33</volume>: <fpage>2609</fpage>–<lpage>2614</lpage>.</citation>
</ref>
<ref id="bibr42-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>YP</given-names></name>
<name><surname>Lin</surname><given-names>YL</given-names></name>
<name><surname>Chuang</surname><given-names>CH</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task</article-title>. <source>J Biomed Sci</source> <volume>16</volume>: <fpage>72</fpage>.</citation>
</ref>
<ref id="bibr43-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luscombe</surname><given-names>GP</given-names></name>
<name><surname>Hopcroft</surname><given-names>RH</given-names></name>
<name><surname>Thomas</surname><given-names>PC</given-names></name>
<etal/></person-group>. (<year>1989</year>) <article-title>The contribution of metabolites to the rapid and potent down-regulation of rat cortical β-adrenoceptors by the putative antidepressant sibutramine hydrochloride</article-title>. <source>Neuropharmacology</source> <volume>28</volume>: <fpage>129</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr44-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mann</surname><given-names>JJ</given-names></name>
<name><surname>Brent</surname><given-names>DA</given-names></name>
<name><surname>Arango</surname><given-names>V</given-names></name>
</person-group> (<year>2001</year>) <article-title>The neurobiology and genetics of suicide and attempted suicide: A focus on the serotonergic system</article-title>. <source>Neuropsychopharmacology</source> <volume>24</volume>: <fpage>467</fpage>–<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr45-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Markovitz</surname><given-names>PJ</given-names></name>
<name><surname>Wagner</surname><given-names>SC</given-names></name>
</person-group> (<year>1995</year>) <article-title>Venlafaxine in the treatment of borderline personality disorder</article-title>. <source>Psychopharmacol Bull</source> <volume>31</volume>: <fpage>773</fpage>–<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr46-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Millan</surname><given-names>MJ</given-names></name>
<name><surname>Gobert</surname><given-names>A</given-names></name>
<name><surname>Girardon</surname><given-names>S</given-names></name>
<name><surname>Dekeyne</surname><given-names>A</given-names></name>
</person-group> (<year>1999</year>) <article-title>Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline</article-title>. <source>Eur J Pharmacol</source> <volume>364</volume>: <fpage>147</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr47-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Millan</surname><given-names>MJ</given-names></name>
<name><surname>Gobert</surname><given-names>A</given-names></name>
<name><surname>Lejeune</surname><given-names>F</given-names></name>
<etal/></person-group>. (<year>2003</year>) <article-title>The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-Hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocotical dopaminergic and adrenergic pathways</article-title>. <source>JPET</source> <volume>306</volume>: <fpage>954</fpage>–<lpage>964</lpage>.</citation>
</ref>
<ref id="bibr48-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milstein</surname><given-names>JA</given-names></name>
<name><surname>Dalley</surname><given-names>JW</given-names></name>
<name><surname>Robbins</surname><given-names>TW</given-names></name>
</person-group> (<year>2010</year>) <article-title>Methylphenidate-induced impulsivity: pharmacological antagonism by beta-adrenoreceptor blockade</article-title>. <source>J Psychopharmacol</source> <volume>24</volume>: <fpage>309</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr49-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Navarra</surname><given-names>R</given-names></name>
<name><surname>Graf</surname><given-names>R</given-names></name>
<name><surname>Huang</surname><given-names>Y</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>32</volume>: <fpage>34</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr50-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nolan</surname><given-names>KA</given-names></name>
<name><surname>D’Angelo</surname><given-names>D</given-names></name>
<name><surname>Hoptman</surname><given-names>MJ</given-names></name>
</person-group> (<year>2011</year>) <article-title>Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls</article-title>. <source>Psychiatry Res</source> <volume>187</volume>: <fpage>301</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr51-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paine</surname><given-names>TA</given-names></name>
<name><surname>Tomasiewicz</surname><given-names>HC</given-names></name>
<name><surname>Zhang</surname><given-names>K</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Sensitivity of the five-choice serial reaction time task to the effects of various psychotropic drugs in Sprague-Dawley Rats</article-title>. <source>Biol Psychiatry</source> <volume>62</volume>: <fpage>687</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr52-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paterson</surname><given-names>NE</given-names></name>
<name><surname>Ricciardi</surname><given-names>J</given-names></name>
<name><surname>Wetzler</surname><given-names>C</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone</article-title>. <source>Neurochem Res</source> <volume>69</volume>: <fpage>41</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr53-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pattij</surname><given-names>T</given-names></name>
<name><surname>Vanderschuren</surname><given-names>LJ</given-names></name>
</person-group> (<year>2008</year>) <article-title>The neuropharmacology of impulsive behaviour</article-title>. <source>Trends Pharmacol Sci</source> <volume>29</volume>: <fpage>192</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr54-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pattij</surname><given-names>T</given-names></name>
<name><surname>Schetters</surname><given-names>D</given-names></name>
<name><surname>Schoffelmeer</surname><given-names>AN</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonists</article-title>. <source>Psychopharmacology (Berl)</source> <volume>219</volume>: <fpage>327</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr55-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perroud</surname><given-names>N</given-names></name>
<name><surname>Baud</surname><given-names>P</given-names></name>
<name><surname>Mouthon</surname><given-names>D</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Impulsivity, aggression and suicidal behaviour in unipolar and bipolar disorders</article-title>. <source>J Affect Disord</source> <volume>134</volume>: <fpage>112</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr56-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Purselle</surname><given-names>DC</given-names></name>
<name><surname>Nemeroff</surname><given-names>CB</given-names></name>
</person-group> (<year>2003</year>) <article-title>Serotonin transporter: A potential substrate in the biology of suicide</article-title>. <source>Neuropsychopharmacology</source> <volume>28</volume>: <fpage>613</fpage>–<lpage>619</lpage>.</citation>
</ref>
<ref id="bibr57-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Puumala</surname><given-names>T</given-names></name>
<name><surname>Sirviö</surname><given-names>J</given-names></name>
</person-group> (<year>1998</year>) <article-title>Changes in activities of dopamine and serotonin systems in the frontal cortex underlie poor choice accuracy and impulsivity of rats in an attention task</article-title>. <source>Neuroscience</source> <volume>83</volume>: <fpage>489</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr58-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reid</surname><given-names>S</given-names></name>
<name><surname>Barbui</surname><given-names>C</given-names></name>
</person-group> (<year>2010</year>) <article-title>Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants</article-title>. <source>BMJ</source> <volume>340</volume>: <fpage>c1468</fpage>.</citation>
</ref>
<ref id="bibr59-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Robbins</surname><given-names>TW</given-names></name>
</person-group> (<year>2002</year>) <article-title>The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry</article-title>. <source>Psychopharmacology</source> <volume>163</volume>: <fpage>362</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr60-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Robinson</surname><given-names>ES</given-names></name>
</person-group> (<year>2012</year>) <article-title>Blockade of noradrenaline re-uptake sites improves accuracy and impulse control in rats performing a five-choice serial reaction time tasks</article-title>. <source>Psychopharmacology (Berl)</source> <volume>219</volume>: <fpage>303</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr61-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Robinson</surname><given-names>ES</given-names></name>
<name><surname>Eagle</surname><given-names>DM</given-names></name>
<name><surname>Mar</surname><given-names>AC</given-names></name>
<etal/></person-group>. (<year>2008a</year>) <article-title>Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat</article-title>. <source>Neuropsychopharmacology</source> <volume>33</volume>: <fpage>1028</fpage>–<lpage>1037</lpage>.</citation>
</ref>
<ref id="bibr62-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Robinson</surname><given-names>ES</given-names></name>
<name><surname>Dalley</surname><given-names>JW</given-names></name>
<name><surname>Theobald</surname><given-names>DE</given-names></name>
<etal/></person-group>. (<year>2008b</year>) <article-title>Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task</article-title>. <source>Neuropsychopharmacology</source> <volume>33</volume>: <fpage>2398</fpage>–<lpage>2406</lpage>.</citation>
</ref>
<ref id="bibr63-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rowley</surname><given-names>HL</given-names></name>
<name><surname>Butler</surname><given-names>SA</given-names></name>
<name><surname>Prow</surname><given-names>MR</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats</article-title>. <source>Synapse</source> <volume>38</volume>: <fpage>167</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr64-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rutter</surname><given-names>JJ</given-names></name>
<name><surname>Gundlah</surname><given-names>C</given-names></name>
<name><surname>Auerbach</surname><given-names>SB</given-names></name>
</person-group> (<year>1995</year>) <article-title>Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation</article-title>. <source>Synapse</source> <volume>20</volume>: <fpage>225</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr65-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soubrié</surname><given-names>P</given-names></name>
</person-group> (<year>1986</year>) <article-title>Reconciling the role of central serotonin neurons in human and animal behavior</article-title>. <source>Behav Brain Sci</source> <volume>9</volume>: <fpage>319</fpage>–<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr66-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
<name><surname>Grady</surname><given-names>MM</given-names></name>
<name><surname>Moret</surname><given-names>C</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants</article-title>. <source>CNS Spectrum</source> <volume>10</volume>: <fpage>732</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr67-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Swanson</surname><given-names>CJ</given-names></name>
<name><surname>Perry</surname><given-names>KW</given-names></name>
<name><surname>Koch-Krueger</surname><given-names>S</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat</article-title>. <source>Neuropharmacology</source> <volume>50</volume>: <fpage>755</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr68-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>DN</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
<name><surname>Holman</surname><given-names>RB</given-names></name>
</person-group> (<year>1998</year>) <article-title>Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex</article-title>. <source>J Psychopharmacol</source> <volume>12</volume>: <fpage>366</fpage>–<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr69-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsutsui-Kimura</surname><given-names>I</given-names></name>
<name><surname>Ohmura</surname><given-names>Y</given-names></name>
<name><surname>Izumi</surname><given-names>T</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>The effects of serotonin and/or noradrenaline reuptake inhibitors on impulsive-like action assessed by the three-choice serial reaction time task: a simple and valid model of impulsive action using rats</article-title>. <source>Behav Pharmacol</source> <volume>20</volume>: <fpage>474</fpage>–<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr70-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walderhaug</surname><given-names>E</given-names></name>
<name><surname>Landrø</surname><given-names>NI</given-names></name>
<name><surname>Magnusson</surname><given-names>A</given-names></name>
</person-group> (<year>2008</year>) <article-title>A synergic effect between lowered serotonin and novel situations on impulsivity measured by CPT</article-title>. <source>J Clin Exp Neuropsychol</source> <volume>30</volume>: <fpage>204</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr71-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walderhaug</surname><given-names>E</given-names></name>
<name><surname>Lunde</surname><given-names>H</given-names></name>
<name><surname>Nordvik</surname><given-names>JE</given-names></name>
<etal/></person-group>. (<year>2002</year>) <article-title>Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals</article-title>. <source>Psychopharmacology (Berl)</source> <volume>164</volume>: <fpage>385</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr72-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilens</surname><given-names>TE</given-names></name>
</person-group> (<year>2006</year>) <article-title>Mechanism of action of agents used in attention-deficit/hyperactivity disorder</article-title>. <source>J Clin Psychiatry</source> <volume>67</volume>: <fpage>32</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr73-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winstanley</surname><given-names>CA</given-names></name>
</person-group> (<year>2011</year>) <article-title>The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders</article-title>. <source>Br J Pharmacol</source> <volume>164</volume>: <year>1301</year> –<year>1321</year>.</citation>
</ref>
<ref id="bibr74-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winstanley</surname><given-names>CA</given-names></name>
<name><surname>Eagle</surname><given-names>DM</given-names></name>
<name><surname>Robbins</surname><given-names>TW</given-names></name>
</person-group> (<year>2006</year>) <article-title>Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies</article-title>. <source>Clin Psychol Rev</source> <volume>26</volume>: <fpage>379</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr75-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winstanley</surname><given-names>CA</given-names></name>
<name><surname>Theobald</surname><given-names>DE</given-names></name>
<name><surname>Dalley</surname><given-names>JW</given-names></name>
<etal/></person-group>. (<year>2004</year>) <article-title>5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion</article-title>. <source>Psychopharmacology</source> <volume>176</volume>: <fpage>376</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr76-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wortley</surname><given-names>KE</given-names></name>
<name><surname>Hughes</surname><given-names>ZA</given-names></name>
<name><surname>Heal</surname><given-names>DJ</given-names></name>
<etal/></person-group>. (<year>1999</year>) <article-title>Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by α2-adrenoceptors</article-title>. <source>Br J Pharmacol</source> <volume>127</volume>: <fpage>1860</fpage>–<lpage>1866</lpage>.</citation>
</ref>
<ref id="bibr77-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Gaalen</surname><given-names>MM</given-names></name>
<name><surname>Koten</surname><given-names>R</given-names></name>
<name><surname>Schoffelmeer</surname><given-names>AN</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Critical involvement of dopaminergic neurotransmission in impulsive decision making</article-title>. <source>Biol Psychiatry</source> <volume>60</volume>: <fpage>66</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr78-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>BK</given-names></name>
<name><surname>Novotney</surname><given-names>S</given-names></name>
</person-group> (<year>1998</year>)<article-title>Regulation of extracellular dopamine by the norepinephrine transporter</article-title>. <source>J Neurochem</source> <volume>71</volume>: <fpage>274</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr79-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zapolski</surname><given-names>TCB</given-names></name>
<name><surname>Settles</surname><given-names>RE</given-names></name>
<name><surname>Cyders</surname><given-names>MA</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Borderline personality disorder, bulimia nervosa, antisocial personality disorder, ADHD, substance use: common threads, common treatment needs, and the nature of impulsivity</article-title>. <source>Indep Pract</source> <volume>30</volume>: <fpage>20</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr80-0269881112466182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Perry</surname><given-names>KW</given-names></name>
<name><surname>Wong</surname><given-names>DT</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex</article-title>. <source>Neuropsychopharmacology</source> <volume>23</volume>: <fpage>250</fpage>–<lpage>262</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>